The tweet was deleted by the author.
But we saved everything 🙂.
Verastem, Inc. has announced the presentation of preclinical results for its investigational oral KRAS G12D (ON/OFF) inhibitor, VS-7375, at this year's AACR Meeting.
The company claims VS-7375 shows significant differentiation from other RAS inhibitors, positioning it as a potential best-in-class therapy in its category. Details regarding the efficacy and comparative advantages of VS-7375 were shared to underscore Verastem, Inc.'s ongoing commitment to innovation in targeted oncology treatments.
The company’s emphasis on advancing targeted oncology treatments builds on strategic priorities detailed in its recent Q4 and year end 2025 results and business update, where Verastem, Inc. outlined continued progress across its RAS/MAPK pipeline. This latest preclinical data on VS-7375 further illustrates the firm’s pursuit of therapeutic innovation within a highly competitive landscape.